Skip to content

Study · Not a test of the peptide alone · 2026

1 result

Positive modulation of glucagon-like peptide 1 (GLP-1) receptor by endogenous haemorphins with implications in glucose metabolism and diabetes.

Khan FB, Alameri RM, Raouf YS, Maurel D, Wani NA, Shmygol A, Anwar I, See HB, Johnstone EKM, Dupuis E, Trinquet E, Pfleger KDG, Oueis E, Ayoub MA

British journal of pharmacology29 Sept 2026

PMID42811773 (opens in a new tab)DOI10.1111/bph.70677 (opens in a new tab)PepBankPUB-42811773
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Orforglipron.

  1. 01LabNot a test of Orforglipron aloneIn vitro (cells)Mechanism

    In cellular receptor assays, LVV-H7 positively modulated GLP-1 receptor action with GLP-1 but not with orforglipron.

    In plain wordsIn cells, LVV-H7 positively modulated receptor action with GLP-1 but not with orforglipron.

    Peptide
    Orforglipron
    Outcome
    Direction not reportedLVV-H7 modulation of orforglipron receptor action
    Study

    n: not reported in source

    HEK293 and INS-1 832/3 cells
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    LVV-H7 has positive action on GLP-1 receptor occurring with GLP-1 but not orforglipron (LY3502970), indicating a peptide-peptide interaction, causing a left shift in GLP-1's dose responses.
    1 context sentence
    Summary · context
    The effect of LVV-haemorphin 7 (LVV-H7) on GLP-1 receptor was assessed in human embryonic kidney (HEK293) and rat insulinoma (INS-1 832/3) cells using bioluminescence resonance energy transfer, downstream signalling, cell viability, insulin synthesis experimental and computational ligand binding analysis.

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.